193P A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors

Autor:	Funan Huang, D. Ji, J. Cao, A. Cleton, Y. Liu, I. Sturm, W. Shen, D. Lu, Q. Wang
Rok vydání:	2016
Předmět:	chemistry.chemical_compound Oncology Refractory chemistry Pharmacokinetics business.industry Regorafenib Medicine Hematology Pharmacology business
Zdroj:	Annals of Oncology. 27:ix60
ISSN:	0923-7534
DOI:	10.1016/s0923-7534(21)00351-3
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb256f0733d9fe1ef420e7897e4da2b https://doi.org/10.1016/s0923-7534(21)00351-3 Zobrazit plný text záznamu